Mesoblast share price on watch after US regulatory approval

The Mesoblast Limited (ASX: MSB) share price could be set to surge after gaining a key regulatory approval from the United States.

| More on:
illustration of half brain half lightbulb

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price could be set to surge after the Aussie biotech company had a huge regulatory breakthrough.

What was the big breakthrough?

Investors were holding out ahead of the US Oncologic Drugs Adviosry Committee (ODAC) meeting to vote on Mesoblast's remestemcel-L treatment (Ryoncil) for paediatric patients with acute-graft versus host disease (aGHVD).

According to an article in the Australian Financial Review (AFR), the ODAC meeting voted 8 to 2 in favour of the Mesoblast drug this morning.

That's good news for the Mesoblast share price, which had tumbled 37% in just 2 days earlier this week.

Investors were pessimistic on the ODAC meeting after a US Food and Drug Administration (FDA) briefing note on Tuesday.

That note questioned how strong the evidence of the treatment's effectiveness was. That caused many to believe the ODAC would come to a similar conclusion.

However, today's news could mean the Mesoblast share price rockets higher. According to the article, the final decision on the Ryoncil drug for marketing is expected to be made by the FDA before 30 September.

That looms as another important milestone, but todaý's vote should boost investors' confidence.

How has the Mesoblast share price performed?

This week alone has been a wild ride for investors.

The Mesoblast share price climbed 9.9% on Monday before freefalling 30.60% on the back of Tuesday's news.

Wednesday saw a further decline of 9.5% before tactical investors picked up the stock cheaply, sparking a 10.1% rally in yesterday's trade.

Despite the volatility, the Mesoblast share price has jumped 64.9% higher in 2020. That's a significant outperformance against the S&P/ASX 200 Index (ASX: XJO), which is down 9.0% this year.

Mesoblast's fellow ASX biotech shares have also had a strong year in the Aussie share market.

Polynovo Ltd (ASX: PNV) shares are up 15.1% this year while the CSL Limited (ASX: CSL) share price has edged 1.0% higher.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »